ADUHELM (aducanumab-avwa) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.
Note: Please speak with your healthcare provider for more information if you think this therapy might be right for you.
How do I make a referral or transition my treatment to Infusion Associates?
3. One of our intake specialists will contact you to confirm receipt of your referral.
4. We will then verify benefits, obtain any required prior authorizations, and contact you to schedule an appointment.